BioCryst Pharmaceuticals Files 8-K on Financials

Ticker: BCRX · Form: 8-K · Filed: May 6, 2024 · CIK: 882796

Sentiment: neutral

Topics: financial-reporting, operations, sec-filing

Related Tickers: BCRX

TL;DR

BioCryst dropped an 8-K on May 6th covering financials and operations.

AI Summary

BioCryst Pharmaceuticals, Inc. filed an 8-K on May 6, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Durham, North Carolina.

Why It Matters

This filing provides crucial updates on BioCryst Pharmaceuticals' financial health and operational performance, which can impact investor decisions and market perception.

Risk Assessment

Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any immediately alarming or significant new information beyond standard reporting requirements.

Key Players & Entities

FAQ

What specific financial information is being reported in this 8-K?

The 8-K filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details of these financial results are not provided in the header information.

What is the primary purpose of this 8-K filing for BioCryst Pharmaceuticals?

The primary purpose is to report on the company's results of operations and financial condition, along with any relevant Regulation FD disclosures and financial exhibits.

When was this 8-K filing submitted to the SEC?

The filing was submitted on May 6, 2024.

Where are BioCryst Pharmaceuticals' principal executive offices located?

The principal executive offices are located at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.

What is BioCryst Pharmaceuticals' fiscal year end?

BioCryst Pharmaceuticals' fiscal year ends on December 31.

Filing Stats: 565 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-05-06 07:03:00

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On May 6, 2024, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing recent corporate developments and its financial results for the first quarter ended March 31, 2024, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein. The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated May 6, 2024 entitled "BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioCryst Pharmaceuticals, Inc. Date: May 6, 2024 By: /s/ Alane Barnes Alane Barnes Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing